Cell replacement therapy for Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 7, 2009, Pages 688-702

  Wijeyekoon, Ruwani ^a   Barker, Roger A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cell replacement; Fetal ventral mesencephalon; Parkinson's disease; Stem cell; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; NERVE GROWTH FACTOR; PLACEBO; PREDNISOLONE;

ADRENAL MEDULLA; ALLOGRAFT; AUTOGRAFT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN TRANSPLANTATION; CAROTID BODY; CELL TRANSPLANTATION; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG RESPONSE; DYSKINESIA; EMBRYONIC STEM CELL; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE DEGENERATION; NEURAL STEM CELL TRANSPLANTATION; NEUROSURGERY; NONHUMAN; PARKINSON DISEASE; PATIENT SAFETY; PIGMENT EPITHELIUM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SYMPATHETIC NERVE CELL; THERAPY EFFECT; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; CELL TRANSPLANTATION; HUMANS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 68949133271     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.10.007     Document Type: Review

References (236)

1. Del Tredici K., Rub U., De Vos R.A., Bohl J.R., and Braak H. Where does Parkinson disease pathology begin in the brain?. J. Neuropathol. Exp. Neurol. 61 (2002) 413-426
2. Braak H., Ghebremedhin E., Rub U., Bratzke H., and Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004) 121-134
3. Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A., and Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21 (2006) 2042-2051
4. Freed W.J., Morihisa J.M., Spoor E., Hoffer B.J., Olson L., Seiger A., and Wyatt R.J. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature 292 (1981) 351-352
5. Freed W.J., Cannon-Spoor H.E., and Krauthamer E. Intrastriatal adrenal medulla grafts in rats. Long-term survival and behavioral effects. J. Neurosurg. 65 (1986) 664-670
6. Morihisa J.M., Nakamura R.K., Freed W.J., Mishkin M., and Wyatt R.J. Transplantation techniques and the survival of adrenal medulla autografts in the primate brain. Ann. N. Y. Acad. Sci. 495 (1987) 599-605
7. Backlund E.O., Granberg P.O., Hamberger B., Knutsson E., Martensson A., Sedvall G., Seiger A., and Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62 (1985) 169-173
8. Lindvall O., Backlund E.O., Farde L., Sedvall G., Freedman R., Hoffer B., Nobin A., Seiger A., and Olson L. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 22 (1987) 457-468
9. Drucker-Colin R., Madrazo I., Ostrosky-Solis F., Shkurovich M., Franco R., and Torres C. Adrenal medullary tissue transplants in the caudate nucleus of Parkinson's patients. Prog. Brain Res. 78 (1988) 567-574
10. Madrazo I., Drucker-Colin R., Diaz V., Martinez-Mata J., Torres C., and Becerril J.J. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 316 (1987) 831-834
11. Freed W.J., Poltorak M., and Becker J.B. Intracerebral adrenal medulla grafts: a review. Exp. Neurol. 110 (1990) 139-166
12. Goetz C.G., Olanow C.W., Koller W.C., Penn R.D., Cahill D., Morantz R., Stebbins G., Tanner C.M., Klawans H.L., and Shannon K.M. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N. Engl. J. Med. 320 (1989) 337-341
13. Olanow C.W., Koller W., Goetz C.G., Stebbins G.T., Cahill D.W., Gauger L.L., Morantz R., Penn R.D., Tanner C.M., Klawans H.L., et al. Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch. Neurol. 47 (1990) 1286-1289
14. Hurtig H., Joyce J., Sladek J.R., and Trojanowski J.Q. Postmortem analysis of adrenal-medulla-to-caudate autograft in a patient with Parkinson's disease. Ann. Neurol. 25 (1989) 607-614
15. Kordower J.H., Cochran E., Penn R.D., and Goetz C.G. Putative chromaffin cell survival and enhanced host-derived TH-fiber innervation following a functional adrenal medulla autograft for Parkinson's disease. Ann. Neurol. 29 (1991) 405-412
16. Kompoliti K., Chu Y., Shannon K.M., and Kordower J.H. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov. Disord. 22 (2007) 1630-1633
17. Date I., Miyoshi Y., Imaoka T., Furuta T., Asari S., and Ohmoto T. Efficacy of pretransection of peripheral nerve for promoting the survival of cografted chromaffin cells and recovery of host dopaminergic fibers in animal models of Parkinson's disease. Neurosci. Res. 20 (1994) 213-221
18. Howel L.L., Byrd L.D., McDonough A.M., Iuvone P.M., and Bakay R.A. Behavioral evaluation of hemiparkinsonian MPTP monkeys following dopamine pharmacological manipulation and adrenal co-graft transplantation. Cell Transplant 9 (2000) 609-622
19. Watts R.L., Subramanian T., Freeman A., Goetz C.G., Penn R.D., Stebbins G.T., Kordower J.H., and Bakay R.A. Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two-year follow-up study. Exp. Neurol. 147 (1997) 510-517
20. Lopez-Lozano J.J., Bravo G., Abascal J., Brera B., and Millan I. Clinical outcome of cotransplantation of peripheral nerve and adrenal medulla in patients with Parkinson's disease. Clinica Puerta de Hierro Neural Transplantation Group. J. Neurosurg. 90 (1999) 875-882
21. Olson L., Backlund E.O., Ebendal T., Freedman R., Hamberger B., Hansson P., Hoffer B., Lindblom U., Meyerson B., Stromberg I., et al. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Arch. Neurol. 48 (1991) 373-381
22. Nakao N., Kakishita K., Uematsu Y., Yoshimasu T., Bessho T., Nakai K., Naito Y., and Itakura T. Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease. J. Neurosurg. 95 (2001) 275-284
23. Nakao N., Shintani-Mizushima A., Kakishita K., and Itakura T. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease. Exp. Neurol. 188 (2004) 65-73
24. Horvath M., Pasztor E., Palkovits M., Solyom A., Tarczy M., Lekka N., and Csanda E. Autotransplantation of superior cervical ganglion to the caudate nucleus in three patients with Parkinson's disease (preliminary report). Neurosurg. Rev. 13 (1990) 119-122
25. Itakura T., Komai N., Ryujin Y., Ooiwa Y., Nakai M., and Yasui M. Autologous transplantation of the cervical sympathetic ganglion into the parkinsonian brain: case report. Neurosurgery 35 (1994) 155-157 (discussion 157-158)
26. Itakura T., Uematsu Y., Nakao N., Nakai E., and Nakai K. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases. Stereotact. Funct. Neurosurg. 69 (1997) 112-115
27. McGregor K.H., Gil J., and Lahiri S. A morphometric study of the carotid body in chronically hypoxic rats. J. Appl. Physiol. 57 (1984) 1430-1438
28. Espejo E.F., Montoro R.J., Armengol J.A., and Lopez-Barneo J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron. 20 (1998) 197-206
29. Toledo-Aral J.J., Mendez-Ferrer S., Pardal R., Echevarria M., and Lopez-Barneo J. Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. J. Neurosci. 23 (2003) 141-148
30. Luquin M.R., Montoro R.J., Guillen J., Saldise L., Insausti R., Del Rio J., and Lopez-Barneo J. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron. 22 (1999) 743-750
31. Arjona V., Minguez-Castellanos A., Montoro R.J., Ortega A., Escamilla F., Toledo-Aral J.J., Pardal R., Mendez-Ferrer S., Martin J.M., Perez M., Katati M.J., Valencia E., Garcia T., and Lopez-Barneo J. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53 (2003) 321-328 (discussion 328-330)
32. Minguez-Castellanos A., Escamilla-Sevilla F., Hotton G.R., Toledo-Aral J.J., Ortega-Moreno A., Mendez-Ferrer S., Martin-Linares J.M., Katati M.J., Mir P., Villadiego J., Meersmans M., Perez-Garcia M., Brooks D.J., Arjona V., and Lopez-Barneo J. Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. J. Neurol. Neurosurg. Psychiatry 78 (2007) 825-831
33. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., and Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003) 589-595
34. McKay B.S., Goodman B., Falk T., and Sherman S.J. Retinal pigment epithelial cell transplantation could provide trophic support in Parkinson's disease: results from an in vitro model system. Exp. Neurol. 201 (2006) 234-243
35. Subramanian T., Marchionini D., Potter E.M., and Cornfeldt M.L. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant 11 (2002) 207-214
36. Doudet D.J., Cornfeldt M.L., Honey C.R., Schweikert A.W., and Allen R.C. PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease. Exp. Neurol. 189 (2004) 361-368
37. Perlow M.J., Freed W.J., Hoffer B.J., Seiger A., Olson L., and Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204 (1979) 643-647
38. Bjorklund A., and Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177 (1979) 555-560
39. Freund T.F., Bolam J.P., Bjorklund A., Stenevi U., Dunnett S.B., Powell J.F., and Smith A.D. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study. J. Neurosci. 5 (1985) 603-616
40. Dunnett S.B., Bjorklund A., Schmidt R.H., Stenevi U., and Iversen S.D. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol. Scand. Suppl. 522 (1983) 29-37
41. Dunnett S.B., Bjorklund A., Stenevi U., and Iversen S.D. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res. 215 (1981) 147-161
42. Dunnett S.B., Bjorklund A., Stenevi U., and Iversen S.D. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res. 229 (1981) 209-217
43. Barker R.A., and Dunnett S.B. Nigral grafts in Animal Models of Parkinson's Disease, Neural Repair, Transplantation and Rehabilitation (1999), Psychology Press 67-92
44. Annett L.E., Dunnett S.B., Martel F.L., Rogers D.C., Ridley R.M., Baker H.F., and Marsden C.D. A functional assessment of embryonic dopaminergic grafts in the marmoset. Prog. Brain Res. 82 (1990) 535-542
45. Annett L.E., Martel F.L., Rogers D.C., Ridley R.M., Baker H.F., and Dunnett S.B. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 125 (1994) 228-246
46. Annett L.E., Torres E.M., Clarke D.J., Ishida Y., Barker R.A., Ridley R.M., Baker H.F., and Dunnett S.B. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. Cell Transplant. 6 (1997) 557-569
47. Fine A., Hunt S.P., Oertel W.H., Nomoto M., Chong P.N., Bond A., Waters C., Temlett J.A., Annett L., Dunnett S., et al. Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Prog. Brain Res. 78 (1988) 479-489
48. Brundin P., Nilsson O.G., Strecker R.E., Lindvall O., Astedt B., and Bjorklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp. Brain Res. 65 (1986) 235-240
49. Madrazo I., Leon V., Torres C., Aguilera M.C., Varela G., Alvarez F., Fraga A., Drucker-Colin R., Ostrosky F., Skurovich M., et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N. Engl. J. Med. 318 (1988) 51
50. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Astedt B., Widner H., Lindholm T., Bjorklund A., Leenders K.L., Rothwell J.C., et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46 (1989) 615-631
51. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K.L., Sawle G., Rothwell J.C., Marsden C.D., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247 (1990) 574-577
52. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., Brundin P., Frackowiak R., Marsden C.D., Odin P., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35 (1994) 172-180
53. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., Lone T., Zhang Y.B., Snyder J.A., Wells T.H., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327 (1992) 1549-1555
54. Spencer D.D., Robbins R.J., Naftolin F., Marek K.L., Vollmer T., Leranth C., Roth R.H., Price L.H., Gjedde A., Bunney B.S., et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 327 (1992) 1541-1548
55. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., Geny C., Samson Y., Hantraye P., Jeny R., et al. Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117 Pt 3 (1994) 487-499
56. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Brown R., Gustavii B., Hagell P., Jahanshahi M., Sawle G., Bjorklund A., Brooks D.J., Marsden C.D., Quinn N.P., and Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42 (1997) 95-107
57. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., and Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56 (1999) 179-187
58. Piccini P., Brooks D.J., Bjorklund A., Gunn R.N., Grasby P.M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H., and Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2 (1999) 1137-1140
59. Piccini P., Lindvall O., Bjorklund A., Brundin P., Hagell P., Ceravolo R., Oertel W., Quinn N., Samuel M., Rehncrona S., Widner H., and Brooks D.J. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48 (2000) 689-695
60. Kordower J.H., Rosenstein J.M., Collier T.J., Burke M.A., Chen E.Y., Li J.M., Martel L., Levey A.E., Mufson E.J., Freeman T.B., and Olanow C.W. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370 (1996) 203-230
61. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., and Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001) 710-719
62. Bjorklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., Levivier M., Peschanski M., Studer L., and Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2 (2003) 437-445
63. Olanow C.W., Freeman T., and Kordower J. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 345 (2001) 146-147 (author reply 147)
64. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., Breeze R., Fahn S., Freed C., and Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 52 (2002) 628-634
65. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., and Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54 (2003) 403-414
66. Freeman T.B., Olanow C.W., Hauser R.A., Nauert G.M., Smith D.A., Borlongan C.V., Sanberg P.R., Holt D.A., Kordower J.H., Vingerhoets F.J., et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 38 (1995) 379-388
67. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., and Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 Pt 7 (2000) 1380-1390
68. Brundin P., Karlsson J., Emgard M., Schierle G.S., Hansson O., Petersen A., and Castilho R.F. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant. 9 (2000) 179-195
69. Laguna Goya R., Tyers P., and Barker R.A. The search for a curative cell therapy in Parkinson's disease. J Neurol Sci 265 (2008) 32-42
70. Sayles M., Jain M., and Barker R.A. The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl. Immunol. 12 (2004) 321-342
71. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., and Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5 (2002) 627-628
72. Cubo E., Gracies J.M., Benabou R., Olanow C.W., Raman R., Leurgans S., and Goetz C.G. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch. Neurol. 58 (2001) 1379-1382
73. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7 (1992) 117-124
74. Barker R.A., Dunnett S.B., Faissner A., and Fawcett J.W. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Exp. Neurol. 141 (1996) 79-93
75. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6 (1999) 461-474
76. Carta M., Carlsson T., Kirik D., and Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 (2007) 1819-1833
77. Carlsson T., Carta M., Winkler C., Bjorklund A., and Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 27 (2007) 8011-8022
78. Lane E.L., Winkler C., Brundin P., and Cenci M.A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 22 (2006) 334-345
79. Carlsson T., Winkler C., Lundblad M., Cenci M.A., Bjorklund A., and Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol. Dis. 21 (2006) 657-668
80. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., Tierney T., Holness R., Dagher A., Trojanowski J.Q., and Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14 (2008) 507-509
81. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., and Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14 (2008) 504-506
82. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Bjorklund A., Widner H., Revesz T., Lindvall O., and Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14 (2008) 501-503
83. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Bjorklund L., Dagher A., and Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128 (2005) 1498-1510
84. Chu Y., and Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 25 (2007) 134-149
85. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Odin P., Wenning G.K., Morrish P., Gustavii B., Bjorklund A., Brooks D.J., Marsden C.D., Quinn N.P., and Lindvall O. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 122 Pt 6 (1999) 1121-1132
86. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., and Chilcote T.J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281 (2006) 29739-29752
87. Armstrong R.J., Hurelbrink C.B., Tyers P., Ratcliffe E.L., Richards A., Dunnett S.B., Rosser A.E., and Barker R.A. The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Exp Neurol 175 (2002) 98-111
88. Deacon T.W., Pakzaban P., Burns L.H., Dinsmore J., and Isacson O. Cytoarchitectonic development, axon-glia relationships, and long distance axon growth of porcine striatal xenografts in rats. Exp. Neurol. 130 (1994) 151-167
89. Isacson O., Deacon T.W., Pakzaban P., Galpern W.R., Dinsmore J., and Burns L.H. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat. Med. 1 (1995) 1189-1194
90. Wictorin K., Brundin P., Gustavii B., Lindvall O., and Bjorklund A. Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts. Nature 347 (1990) 556-558
91. Hurelbrink C.B., Armstrong R.J., Dunnett S.B., Rosser A.E., and Barker R.A. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur. J. Neurosci. 15 (2002) 1255-1266
92. Schumacher J.M., Ellias S.A., Palmer E.P., Kott H.S., Dinsmore J., Dempsey P.K., Fischman A.J., Thomas C., Feldman R.G., Kassissieh S., Raineri R., Manhart C., Penney D., Fink J.S., and Isacson O. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54 (2000) 1042-1050
93. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., Edge A., Penney D., Kassissieh S., Dempsey P., and Isacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. 3 (1997) 350-353
94. Li J.Y., Christophersen N.S., Hall V., Soulet D., and Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci 31 (2008) 146-153
95. Evans M.J., and Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 292 (1981) 154-156
96. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 7634-7638
97. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., and Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998) 1145-1147
98. Wilson S.I., and Edlund T. Neural induction: toward a unifying mechanism. Nat. Neurosci. 4 Suppl. (2001) 1161-1168
99. Ben-Hur T., Idelson M., Khaner H., Pera M., Reinhartz E., Itzik A., and Reubinoff B.E. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 22 (2004) 1246-1255
100. Gerrard L., Rodgers L., and Cui W. Differentiation of human embryonic stem cells to neural lineages in adherent culture by blocking bone morphogenetic protein signaling. Stem Cells 23 (2005) 1234-1241
101. Iacovitti L., Donaldson A.E., Marshall C.E., Suon S., and Yang M. A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: studies in vitro and in vivo. Brain Res. 1127 (2007) 19-25
102. Bjorklund L.M., Sanchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., Brownell A.L., Jenkins B.G., Wahlestedt C., Kim K.S., and Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2344-2349
103. Li M., Pevny L., Lovell-Badge R., and Smith A. Generation of purified neural precursors from embryonic stem cells by lineage selection. Curr Biol 8 (1998) 971-974
104. Ying Q.L., Stavridis M., Griffiths D., Li M., and Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat. Biotechnol. 21 (2003) 183-186
105. Conti L., Pollard S.M., Gorba T., Reitano E., Toselli M., Biella G., Sun Y., Sanzone S., Ying Q.L., Cattaneo E., and Smith A. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 3 (2005) e283
106. Reubinoff B.E., Itsykson P., Turetsky T., Pera M.F., Reinhartz E., Itzik A., and Ben-Hur T. Neural progenitors from human embryonic stem cells. Nat Biotechnol 19 (2001) 1134-1140
107. Zhang S.C., Wernig M., Duncan I.D., Brustle O., and Thomson J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19 (2001) 1129-1133
108. Kawasaki H., Mizuseki K., Nishikawa S., Kaneko S., Kuwana Y., Nakanishi S., Nishikawa S.I., and Sasai Y. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28 (2000) 31-40
109. Zeng X., Cai J., Chen J., Luo Y., You Z.B., Fotter E., Wang Y., Harvey B., Miura T., Backman C., Chen G.J., Rao M.S., and Freed W.J. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22 (2004) 925-940
110. Brederlau A., Correia A.S., Anisimov S.V., Elmi M., Paul G., Roybon L., Morizane A., Bergquist F., Riebe I., Nannmark U., Carta M., Hanse E., Takahashi J., Sasai Y., Funa K., Brundin P., Eriksson P.S., and Li J.Y. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24 (2006) 1433-1440
111. Lee S.H., Lumelsky N., Studer L., Auerbach J.M., and McKay R.D. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat. Biotechnol. 18 (2000) 675-679
112. Takagi Y., Takahashi J., Saiki H., Morizane A., Hayashi T., Kishi Y., Fukuda H., Okamoto Y., Koyanagi M., Ideguchi M., Hayashi H., Imazato T., Kawasaki H., Suemori H., Omachi S., Iida H., Itoh N., Nakatsuji N., Sasai Y., and Hashimoto N. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J. Clin. Invest. 115 (2005) 102-109
113. Schulz T.C., Noggle S.A., Palmarini G.M., Weiler D.A., Lyons I.G., Pensa K.A., Meedeniya A.C., Davidson B.P., Lambert N.A., and Condie B.G. Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. Stem Cells 22 (2004) 1218-1238
114. Yan Y., Yang D., Zarnowska E.D., Du Z., Werbel B., Valliere C., Pearce R.A., Thomson J.A., and Zhang S.C. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 23 (2005) 781-790
115. Yang D., Zhang Z.J., Oldenburg M., Ayala M., and Zhang S.C. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 26 (2008) 55-63
116. Barberi T., Klivenyi P., Calingasan N.Y., Lee H., Kawamata H., Loonam K., Perrier A.L., Bruses J., Rubio M.E., Topf N., Tabar V., Harrison N.L., Beal M.F., Moore M.A., and Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat. Biotechnol. 21 (2003) 1200-1207
117. Perrier A.L., Tabar V., Barberi T., Rubio M.E., Bruses J., Topf N., Harrison N.L., and Studer L. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12543-12548
118. Park C.H., Minn Y.K., Lee J.Y., Choi D.H., Chang M.Y., Shim J.W., Ko J.Y., Koh H.C., Kang M.J., Kang J.S., Rhie D.J., Lee Y.S., Son H., Moon S.Y., Kim K.S., and Lee S.H. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J. Neurochem. 92 (2005) 1265-1276
119. Sonntag K.C., Pruszak J., Yoshizaki T., van Arensbergen J., Sanchez-Pernaute R., and Isacson O. Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 25 (2007) 411-418
120. Roy N.S., Cleren C., Singh S.K., Yang L., Beal M.F., and Goldman S.A. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12 (2006) 1259-1268
121. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., Lee S.H., Nguyen J., Sanchez-Pernaute R., Bankiewicz K., and McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 (2002) 50-56
122. Chung S., Hedlund E., Hwang M., Kim D.W., Shin B.S., Hwang D.Y., Jung Kang U., Isacson O., and Kim K.S. The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. Mol. Cell Neurosci. 28 (2005) 241-252
123. Andersson E., Tryggvason U., Deng Q., Friling S., Alekseenko Z., Robert B., Perlmann T., and Ericson J. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124 (2006) 393-405
124. Kim D.W., Chung S., Hwang M., Ferree A., Tsai H.C., Park J.J., Nam T.S., Kang U.J., Isacson O., and Kim K.S. Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells 24 (2006) 557-567
125. Cho M.S., Lee Y.E., Kim J.Y., Chung S., Cho Y.H., Kim D.S., Kang S.M., Lee H., Kim M.H., Kim J.H., Leem J.W., Oh S.K., Choi Y.M., Hwang D.Y., Chang J.W., and Kim D.W. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3392-3397
126. Paul G., Christophersen N.S., Raymon H., Kiaer C., Smith R., and Brundin P. Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line-studies in vitro and after intracerebral grafting in vivo. Mol. Cell Neurosci. 34 (2007) 390-399
127. Christophersen N.S., and Brundin P. Large stem cell grafts could lead to erroneous interpretations of behavioral results?. Nat. Med. 13 (2007) 118 (author reply 118-119)
128. Nussbaum J., Minami E., Laflamme M.A., Virag J.A., Ware C.B., Masino A., Muskheli V., Pabon L., Reinecke H., and Murry C.E. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 21 (2007) 1345-1357
129. Parish C.L., Parisi S., Persico M.G., Arenas E., and Minchiotti G. Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease. Stem Cells 23 (2005) 471-476
130. Schuldiner M., Itskovitz-Eldor J., and Benvenisty N. Selective ablation of human embryonic stem cells expressing a "suicide" gene. Stem Cells 21 (2003) 257-265
131. Jung J., Hackett N.R., Pergolizzi R.G., Pierre-Destine L., Krause A., and Crystal R.G. Ablation of tumor-derived stem cells transplanted to the central nervous system by genetic modification of embryonic stem cells with a suicide gene. Hum. Gene Ther. 18 (2007) 1182-1192
132. Chung S., Shin B.S., Hedlund E., Pruszak J., Ferree A., Kang U.J., Isacson O., and Kim K.S. Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J. Neurochem. 97 (2006) 1467-1480
133. Pruszak J., Sonntag K.C., Aung M.H., Sanchez-Pernaute R., and Isacson O. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 25 (2007) 2257-2268
134. Bieberich E., Silva J., Wang G., Krishnamurthy K., and Condie B.G. Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants. J. Cell Biol. 167 (2004) 723-734
135. Bjornson C.R., Rietze R.L., Reynolds B.A., Magli M.C., and Vescovi A.L. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283 (1999) 534-537
136. Davis A.A., and Temple S. A self-renewing multipotential stem cell in embryonic rat cerebral cortex. Nature 372 (1994) 263-266
137. Flax J.D., Aurora S., Yang C., Simonin C., Wills A.M., Billinghurst L.L., Jendoubi M., Sidman R.L., Wolfe J.H., Kim S.U., and Snyder E.Y. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat. Biotechnol. 16 (1998) 1033-1039
138. Smith R., Bagga V., and Fricker-Gates R.A. Embryonic neural progenitor cells: the effects of species, region, and culture conditions on long-term proliferation and neuronal differentiation. J Hematother Stem Cell Res 12 (2003) 713-725
139. Gage F.H., Ray J., and Fisher L.J. Isolation, characterization, and use of stem cells from the CNS. Annu. Rev. Neurosci. 18 (1995) 159-192
140. Gage F.H. Mammalian neural stem cells. Science 287 (2000) 1433-1438
141. Temple S. The development of neural stem cells. Nature 414 (2001) 112-117
142. Studer L., Tabar V., and McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1 (1998) 290-295
143. Svendsen C.N., Clarke D.J., Rosser A.E., and Dunnett S.B. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp. Neurol. 137 (1996) 376-388
144. Ostenfeld T., and Svendsen C.N. Requirement for neurogenesis to proceed through the division of neuronal progenitors following differentiation of epidermal growth factor and fibroblast growth factor-2-responsive human neural stem cells. Stem Cells 22 (2004) 798-811
145. Horiguchi S., Takahashi J., Kishi Y., Morizane A., Okamoto Y., Koyanagi M., Tsuji M., Tashiro K., Honjo T., Fujii S., and Hashimoto N. Neural precursor cells derived from human embryonic brain retain regional specificity. J. Neurosci. Res. 75 (2004) 817-824
146. Schwarz S.C., Wittlinger J., Schober R., Storch A., and Schwarz J. Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with cyclosporine A. Parkinsonism Relat Disord 12 (2006) 302-308
147. Studer L., Csete M., Lee S.H., Kabbani N., Walikonis J., Wold B., and McKay R. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J. Neurosci. 20 (2000) 7377-7383
148. Nishino H., Hida H., Takei N., Kumazaki M., Nakajima K., and Baba H. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum. Exp. Neurol. 164 (2000) 209-214
149. Sawamoto K., Nakao N., Kakishita K., Ogawa Y., Toyama Y., Yamamoto A., Yamaguchi M., Mori K., Goldman S.A., Itakura T., and Okano H. Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J. Neurosci. 21 (2001) 3895-3903
150. Timmer M., Grosskreutz J., Schlesinger F., Krampfl K., Wesemann M., Just L., Bufler J., and Grothe C. Dopaminergic properties and function after grafting of attached neural precursor cultures. Neurobiol. Dis. 21 (2006) 587-606
151. Carvey P.M., Ling Z.D., Sortwell C.E., Pitzer M.R., McGuire S.O., Storch A., and Collier T.J. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp. Neurol. 171 (2001) 98-108
152. Park C.H., Kang J.S., Shin Y.H., Chang M.Y., Chung S., Koh H.C., Zhu M.H., Oh S.B., Lee Y.S., Panagiotakos G., Tabar V., Studer L., and Lee S.H. Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons. FASEB J. 20 (2006) 2553-2555
153. O'Keeffe F.E., Scott S.A., Tyers P., O'Keeffe G.W., Dalley J.W., Zufferey R., and Caldwell M.A. Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain 131 (2008) 630-641
154. Kim H.J., Sugimori M., Nakafuku M., and Svendsen C.N. Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1. Exp. Neurol. 203 (2007) 394-405
155. Andersson E.K., Irvin D.K., Ahlsio J., and Parmar M. Ngn2 and Nurr1 act in synergy to induce midbrain dopaminergic neurons from expanded neural stem and progenitor cells. Exp. Cell Res. 313 (2007) 1172-1180
156. Roybon L., Hjalt T., Christophersen N.S., Li J.Y., and Brundin P. Effects on differentiation of embryonic ventral midbrain progenitors by Lmx1a, Msx1, Ngn2, and Pitx3. J. Neurosci. 28 (2008) 3644-3656
157. Morizane A., Li J.Y., and Brundin P. From bench to bed: the potential of stem cells for the treatment of Parkinson's disease. Cell Tissue Res. 331 (2008) 323-336
158. Svendsen C.N., Caldwell M.A., Shen J., ter Borg M.G., Rosser A.E., Tyers P., Karmiol S., and Dunnett S.B. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp. Neurol. 148 (1997) 135-146
159. Storch A., Paul G., Csete M., Boehm B.O., Carvey P.M., Kupsch A., and Schwarz J. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp. Neurol. 170 (2001) 317-325
160. Sanchez-Pernaute R., Studer L., Bankiewicz K.S., Major E.O., and McKay R.D. In vitro generation and transplantation of precursor-derived human dopamine neurons. J. Neurosci. Res. 65 (2001) 284-288
161. Wang X., Lu Y., Zhang H., Wang K., He Q., Wang Y., Liu X., and Li L. Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease. Int. J. Dev. Neurosci. 22 (2004) 175-183
162. Riaz S.S., Theofilopoulos S., Jauniaux E., Stern G.M., and Bradford H.F. The differentiation potential of human foetal neuronal progenitor cells in vitro. Brain Res. Dev. Brain Res. 153 (2004) 39-51
163. Yang M., Donaldson A.E., Marshall C.E., Shen J., and Iacovitti L. Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo. Cell Transplant. 13 (2004) 535-547
164. Christophersen N.S., Meijer X., Jorgensen J.R., Englund U., Gronborg M., Seiger A., Brundin P., and Wahlberg L.U. Induction of dopaminergic neurons from growth factor expanded neural stem/progenitor cell cultures derived from human first trimester forebrain. Brain Res. Bull. 70 (2006) 457-466
165. Liste I., Garcia-Garcia E., and Martinez-Serrano A. The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-XL, both in vitro and in vivo. J. Neurosci. 24 (2004) 10786-10795
166. Liste I., Garcia-Garcia E., Bueno C., and Martinez-Serrano A. Bcl-XL modulates the differentiation of immortalized human neural stem cells. Cell Death Differ. 14 (2007) 1880-1892
167. Altman J., and Das G.D. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J. Comp. Neurol. 124 (1965) 319-335
168. Reynolds B.A., and Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255 (1992) 1707-1710
169. Lois C., and Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 2074-2077
170. Morshead C.M., Reynolds B.A., Craig C.G., McBurney M.W., Staines W.A., Morassutti D., Weiss S., and van der Kooy D. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron 13 (1994) 1071-1082
171. Bayer S.A., Yackel J.W., and Puri P.S. Neurons in the rat dentate gyrus granular layer substantially increase during juvenile and adult life. Science 216 (1982) 890-892
172. Palmer T.D., Ray J., and Gage F.H. FGF-2-responsive neuronal progenitors reside in proliferative and quiescent regions of the adult rodent brain. Mol. Cell Neurosci. 6 (1995) 474-486
173. Kuhn H.G., Dickinson-Anson H., and Gage F.H. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J. Neurosci. 16 (1996) 2027-2033
174. Roy N.S., Wang S., Jiang L., Kang J., Benraiss A., Harrison-Restelli C., Fraser R.A., Couldwell W.T., Kawaguchi A., Okano H., Nedergaard M., and Goldman S.A. In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat. Med. 6 (2000) 271-277
175. Palmer T.D., Markakis E.A., Willhoite A.R., Safar F., and Gage F.H. Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J. Neurosci. 19 (1999) 8487-8497
176. Markakis E.A., Palmer T.D., Randolph-Moore L., Rakic P., and Gage F.H. Novel neuronal phenotypes from neural progenitor cells. J. Neurosci. 24 (2004) 2886-2897
177. Tropepe V., Coles B.L., Chiasson B.J., Horsford D.J., Elia A.J., McInnes R.R., and van der Kooy D. Retinal stem cells in the adult mammalian eye. Science 287 (2000) 2032-2036
178. Weiss S., Dunne C., Hewson J., Wohl C., Wheatley M., Peterson A.C., and Reynolds B.A. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J. Neurosci. 16 (1996) 7599-7609
179. Armstrong R.J., and Barker R.A. Neurodegeneration: a failure of neuroregeneration?. Lancet 358 (2001) 1174-1176
180. Lie D.C., Dziewczapolski G., Willhoite A.R., Kaspar B.K., Shults C.W., and Gage F.H. The adult substantia nigra contains progenitor cells with neurogenic potential. J. Neurosci. 22 (2002) 6639-6649
181. Hermann A., Maisel M., Wegner F., Liebau S., Kim D.W., Gerlach M., Schwarz J., Kim K.S., and Storch A. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells 24 (2006) 949-964
182. Zhao M., Momma S., Delfani K., Carlen M., Cassidy R.M., Johansson C.B., Brismar H., Shupliakov O., Frisen J., and Janson A.M. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7925-7930
183. Shan X., Chi L., Bishop M., Luo C., Lien L., Zhang Z., and Liu R. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells 24 (2006) 1280-1287
184. Frielingsdorf H., Schwarz K., Brundin P., and Mohapel P. No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10177-10182
185. Chen Y., Ai Y., Slevin J.R., Maley B.E., and Gash D.M. Progenitor proliferation in the adult hippocampus and substantia nigra induced by glial cell line-derived neurotrophic factor. Exp. Neurol. 196 (2005) 87-95
186. Mohapel P., Frielingsdorf H., Haggblad J., Zachrisson O., and Brundin P. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience 132 (2005) 767-776
187. Steiner B., Winter C., Hosman K., Siebert E., Kempermann G., Petrus D.S., and Kupsch A. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 199 (2006) 291-300
188. Van Kampen J.M., Hagg T., and Robertson H.A. Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur. J. Neurosci. 19 (2004) 2377-2387
189. Hoglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., and Hirsch E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7 (2004) 726-735
190. Pardal R., Ortega-Saenz P., Duran R., and Lopez-Barneo J. Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 131 (2007) 364-377
191. Bianco P., Riminucci M., Gronthos S., and Robey P.G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19 (2001) 180-192
192. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., Reyes M., Lenvik T., Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., Low W.C., Largaespada D.A., and Verfaillie C.M. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
193. Kim S., Honmou O., Kato K., Nonaka T., Houkin K., Hamada H., and Kocsis J.D. Neural differentiation potential of peripheral blood- and bone-marrow-derived precursor cells. Brain Res. 1123 (2006) 27-33
194. Dezawa M., Kanno H., Hoshino M., Cho H., Matsumoto N., Itokazu Y., Tajima N., Yamada H., Sawada H., Ishikawa H., Mimura T., Kitada M., Suzuki Y., and Ide C. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J. Clin. Invest. 113 (2004) 1701-1710
195. Wagers A.J., Sherwood R.I., Christensen J.L., and Weissman I.L. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297 (2002) 2256-2259
196. Alvarez-Dolado M., Pardal R., Garcia-Verdugo J.M., Fike J.R., Lee H.O., Pfeffer K., Lois C., Morrison S.J., and Alvarez-Buylla A. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425 (2003) 968-973
197. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 69 (2007) 1-9
198. Li Y., Chen J., Chen X.G., Wang L., Gautam S.C., Xu Y.X., Katakowski M., Zhang L.J., Lu M., Janakiraman N., and Chopp M. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 59 (2002) 514-523
199. Wilmut I., Schnieke A.E., McWhir J., Kind A.J., and Campbell K.H. Viable offspring derived from fetal and adult mammalian cells. Nature 385 (1997) 810-813
200. Tada M., Takahama Y., Abe K., Nakatsuji N., and Tada T. Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr. Biol. 11 (2001) 1553-1558
201. Cowan C.A., Atienza J., Melton D.A., and Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 309 (2005) 1369-1373
202. Takahashi K., and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006) 663-676
203. Rodolfa K.T., and Eggan K. A transcriptional logic for nuclear reprogramming. Cell 126 (2006) 652-655
204. Maherali N., Sridharan R., Xie W., Utikal J., Eminli S., Arnold K., Stadtfeld M., Yachechko R., Tchieu J., Jaenisch R., Plath K., and Hochedlinger K. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell 1 (2007) 55-70
205. Okita K., Ichisaka T., and Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 448 (2007) 313-317
206. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., Bernstein B.E., and Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448 (2007) 318-324
207. Meissner A., Wernig M., and Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat. Biotechnol. 25 (2007) 1177-1181
208. Hanna J., Markoulaki S., Schorderet P., Carey B.W., Beard C., Wernig M., Creyghton M.P., Steine E.J., Cassady J.P., Foreman R., Lengner C.J., Dausman J.A., and Jaenisch R. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133 (2008) 250-264
209. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., Chiba T., and Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321 (2008) 699-702
210. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
211. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., and Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451 (2008) 141-146
212. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., Clark A.T., and Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2883-2888
213. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin II., and Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
214. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., Broccoli V., Constantine-Paton M., Isacson O., and Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5856-5861
215. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., and Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science 279 (1998) 349-352
216. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
217. Mali P., Ye Z., Hommond H.H., Yu X., Lin J., Chen G., Zou J., and Cheng L. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells (2008)
218. Liao J., Wu Z., Wang Y., Cheng L., Cui C., Gao Y., Chen T., Rao L., Chen S., Jia N., Dai H., Xin S., Kang J., Pei G., and Xiao L. Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. Cell Res. 18 (2008) 600-603
219. Mikkelsen T.S., Hanna J., Zhang X., Ku M., Wernig M., Schorderet P., Bernstein B.E., Jaenisch R., Lander E.S., and Meissner A. Dissecting direct reprogramming through integrative genomic analysis. Nature 454 (2008) 49-55
220. Shi Y., Do J.T., Desponts C., Hahm H.S., Scholer H.R., and Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2 (2008) 525-528
221. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., and Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26 (2008) 101-106
222. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., and Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54 (2003) 93-101
223. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol. 23 (2000) 34-44
224. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., McDermott M., Seibyl J., Weiner W., Musch B., Kamp C., Welsh M., Shinaman A., Pahwa R., Barclay L., Hubble J., LeWitt P., Miyasaki J., Suchowersky O., Stacy M., Russell D.S., Ford B., Hammerstad J., Riley D., Standaert D., Wooten F., Factor S., Jankovic J., Atassi F., Kurlan R., Panisset M., Rajput A., Rodnitzky R., Shults C., Petsinger G., Waters C., Pfeiffer R., Biglan K., Borchert L., Montgomery A., Sutherland L., Weeks C., DeAngelis M., Sime E., Wood S., Pantella C., Harrigan M., Fussell B., Dillon S., Alexander-Brown B., Rainey P., Tennis M., Rost-Ruffner E., Brown D., Evans S., Berry D., Hall J., Shirley T., Dobson J., Fontaine D., Pfeiffer B., Brocht A., Bennett S., Daigneault S., Hodgeman K., O'Connell C., Ross T., Richard K., and Watts A. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61 (2004) 1044-1053
225. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59 (2002) 1937-1943
226. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57 (2005) 298-302
227. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., and Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006) 459-466
228. Yasuhara T., Shingo T., Muraoka K., Kobayashi K., Takeuchi A., Yano A., Wenji Y., Kameda M., Matsui T., Miyoshi Y., and Date I. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J. Neurosurg. 102 (2005) 80-89
229. Sajadi A., Bensadoun J.C., Schneider B.L., Lo Bianco C., and Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis. 22 (2006) 119-129
230. Jr. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., Taylor R., Cahn-Weiner D.A., Stoessl A.J., Olanow C.W., and Bartus R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7 (2008) 400-408
231. Azzouz M., Martin-Rendon E., Barber R.D., Mitrophanous K.A., Carter E.E., Rohll J.B., Kingsman S.M., Kingsman A.J., and Mazarakis N.D. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22 (2002) 10302-10312
232. Palfi S., Leventhal L., Chu Y., Ma S.Y., Emborg M., Bakay R., Deglon N., Hantraye P., Aebischer P., and Kordower J.H. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci. 22 (2002) 4942-4954
233. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., and During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2105
234. Spheramine - (http://www.titanpharm.com/products-trials.php.
235. Porcine Xenografts, Genzyme Press Release 2001 - http://www.genzyme.com/corp/media/Genl%20PR%20-20041901.asp; http://www.genvec.com/go.cfm?do=Press.View&prid=141.
236. ADAGIO Trial Press Release 2008 - http://www.tevapharm.com/pr/2008/pr_766.asp.